{"nctId":"NCT00169442","briefTitle":"Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infants","startDateStruct":{"date":"2005-02-10","type":"ACTUAL"},"conditions":["Whole Cell Pertussis","Diphtheria","Hepatitis B","Tetanus","Haemophilus Influenzae Type b"],"count":745,"armGroups":[{"label":"Tritanrix-HepB/Hiberix Kft. Mix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix™-HepB/Hiberix™ Kft."]},{"label":"Tritanrix-HepB/Hiberix Kft. Ref Group","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix™-HepB/Hiberix™ Kft.","Biological: Tritanrix™-HepB/Hiberix™"]},{"label":"HB Tritanrix-HepB/Hiberix Kft. Mix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix™-HepB/Hiberix™ Kft."]},{"label":"Tritanrix-HepB Kft.+Hiberix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Hiberix™","Biological: Tritanrix™-HepB Kft"]},{"label":"PRP Tritanrix-HepB Kft. Mix Group","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix™-HepB/Hiberix™ Kft.","Biological: Polyribosil-Ribitol-Phosphate (PRP) vaccine","Biological: Tritanrix™-HepB Kft"]},{"label":"PRP Tritanrix-HepB Kft. Ref Group","type":"EXPERIMENTAL","interventionNames":["Biological: Tritanrix™-HepB/Hiberix™","Biological: Polyribosil-Ribitol-Phosphate (PRP) vaccine","Biological: Tritanrix™-HepB Kft"]}],"interventions":[{"name":"Tritanrix™-HepB/Hiberix™ Kft.","otherNames":["DTPw-HBV/Hib Kft"]},{"name":"Tritanrix™-HepB/Hiberix™","otherNames":["DTPw-HBV/Hib"]},{"name":"Hiberix™","otherNames":[]},{"name":"Polyribosil-Ribitol-Phosphate (PRP) vaccine","otherNames":[]},{"name":"Tritanrix™-HepB Kft","otherNames":["DTPw-HBV Kft"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nFor subjects receiving Plain PRP followed by DTPw-HBV:\n\nMale or female infant, 10 to 11 months of age, who previously completed the three-dose primary vaccination course with the DTPw-HBV/Hib vaccine.\n\nFor subjects receiving DTPw-HBV/Hib or DTPw-HBV + Hib:\n\nMale or female infant, 15-18 months of age, who previously completed the three-dose primary vaccination course with the DTPw-HBV/Hib vaccine.\n\nFor all subjects:\n\n* Subjects who the investigator believes that their parent/guardian can and will comply with the requirements of the protocol.\n* Free of obvious health problems as established by medical history and clinical examination\n\nExclusion criteria:\n\n* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding administration of the study vaccine, or planned use during the study period.\n* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to administration of the study vaccine.\n* Planned administration/administration of a vaccine not foreseen by the study protocol starting 30 days before and ending 30 days after administration of the study vaccine with the exception of oral polio vaccine.","healthyVolunteers":true,"sex":"ALL","minimumAge":"10 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL","description":"The number of subjects with anti-PRP antibody concentrations equal to or above (≥) 0.15 μg/mL and ≥ 1.0 μg/mL, at one month after the PRP challenge.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.","description":"The number of subjects with anti-PRP antibody concentrations equal to or above (≥) 0.15 μg/mL and ≥ 1.0 μg/mL, at one month post-booster vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"70","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against Diphteria (D) and Tetanus (T)","description":"A seroprotected subject was defined as a vaccinated subject, with anti-D and anti-T antibody concentrations equal to or above (≥) 0.1 International Units per milliliter (IU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"68","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"73","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"88","spread":null},{"groupId":"OG003","value":"74","spread":null}]}]}]},{"type":"PRIMARY","title":"Seroprotection Rates for Anti-D Antibodies","description":"The seroprotection rate is defined as the estimated proportion of subjects with protective antibodies as assessed by the Enzyme-Linked Immunosorbent Assay (ELISA) (antibody concentration ≥ 0.1 IU/mL), or by Vero-cell neutralisation assay (antibody concentration ≥ 0.016 IU/mL), for subjects seronegative as assessed by ELISA.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null},{"groupId":"OG002","value":"100","spread":null},{"groupId":"OG003","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against Hepatitis B Surface Antigen (HBs)","description":"A seroprotected subject was defined as a vaccinated subject with an anti-HBs antibody concentration equal to or above (≥) 10 milli International Units per milliliter (mIU/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Seroprotected Subjects Against Bordetella Pertussis (BPT)","description":"A seroprotected subject was defined as a vaccinated subject with an anti-BPT antibody concentration equal to or above (≥) 15 ELISA units per milliliter (EL.U/mL).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"65","spread":null},{"groupId":"OG002","value":"85","spread":null},{"groupId":"OG003","value":"69","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Booster Response to BPT Antigen","description":"The booster response was defined as:\n\n* an anti-BPT antibody concentration equal to or above (≥) the cut-off value (15 EL.U/mL) at post-booster vaccination in subjects seronegative (anti-BPT antibody concentration \\< 15 EL.U/mL) prior to administration of the booster dose; or\n* at least a 2-fold increase in antibody concentration from pre- to post-vaccination time points, in subjects who were seropositive (anti-BPT antibody concentration ≥ 15 EL.U/mL) prior to the administration of the booster dose.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"67","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-PRP Antibody Concentrations","description":"Anti-PRP antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in microgram per milliliter (μg/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.190","spread":null},{"groupId":"OG001","value":"22.727","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-PRP Antibody Concentrations.","description":"Anti-PRP antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in microgram per milliliter (μg/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.670","spread":null},{"groupId":"OG001","value":"81.681","spread":null},{"groupId":"OG002","value":"58.669","spread":null},{"groupId":"OG003","value":"113.073","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-D and Anti-T Antibody Concentrations","description":"Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.087","spread":null},{"groupId":"OG001","value":"1.812","spread":null},{"groupId":"OG002","value":"3.452","spread":null},{"groupId":"OG003","value":"3.128","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.371","spread":null},{"groupId":"OG001","value":"12.181","spread":null},{"groupId":"OG002","value":"12.838","spread":null},{"groupId":"OG003","value":"16.822","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-HBs Antibody Concentrations","description":"Anti-HBs antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in milli International Units per milliliter (mIU/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2400.0","spread":null},{"groupId":"OG001","value":"1628.3","spread":null},{"groupId":"OG002","value":"2467.9","spread":null},{"groupId":"OG003","value":"2465.1","spread":null}]}]}]},{"type":"PRIMARY","title":"Anti-BPT Antibody Concentrations","description":"Anti-BPT antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"118.8","spread":null},{"groupId":"OG002","value":"97.6","spread":null},{"groupId":"OG003","value":"93.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL","description":"The number of subjects with anti-PRP antibody concentrations equal to or above (≥) 0.15 μg/mL and ≥ 1.0 μg/mL, prior to the PRP challenge.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"41","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"34","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-PRP Antibody Concentrations ≥ 0.15 μg/mL and ≥ 1.0 μg/mL.","description":"The number of subjects with anti-PRP antibody concentrations equal to or above (≥) 0.15 μg/mL and ≥ 1.0 μg/mL, prior to the booster vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"74","spread":null},{"groupId":"OG001","value":"69","spread":null},{"groupId":"OG002","value":"84","spread":null},{"groupId":"OG003","value":"72","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"66","spread":null},{"groupId":"OG003","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-D and Anti-T Antibody Concentrations ≥ the Cut-off Value","description":"The number of subjects with anti-D antibody concentrations equal to or above (≥) the cut-off value of 0.1 IU/mL as assessed by ELISA, (or ≥ 0.016 IU/mL as assessed by the neutralisation assay on Vero cells in subjects seronegative by ELISA testing) and, the number of subjects with anti-T antibody concentrations ≥ the cut-off value of 0.1 IU/mL as assessed by ELISA.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"24","spread":null},{"groupId":"OG002","value":"58","spread":null},{"groupId":"OG003","value":"46","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72","spread":null},{"groupId":"OG001","value":"67","spread":null},{"groupId":"OG002","value":"86","spread":null},{"groupId":"OG003","value":"69","spread":null}]}]}]},{"type":"SECONDARY","title":"Seroprotection Rates for Anti-D Antibodies","description":"The seroprotection rate is defined as the estimated proportion of subjects with protective antibodies as assessed by ELISA (antibody concentration ≥ 0.1 IU/mL), or by Vero-cell neutralisation assay (antibody concentration ≥ 0.016 IU/mL), for subjects seronegative as assessed by ELISA.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"71.6","spread":null},{"groupId":"OG002","value":"95.5","spread":null},{"groupId":"OG003","value":"85.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-HBs Antibody Concentrations ≥ the Cut-off Value","description":"The number of subjects with anti-HBs antibody concentrations equal to or above (≥) the cut-off value of 10 mIU/mL, prior to the booster vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"69","spread":null},{"groupId":"OG003","value":"56","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Anti-BPT Antibody Concentrations ≥ the Cut-off Value","description":"The number of subjects with anti-BPT antibody concentrations equal to or above (≥) the cut-off value of 15 EL.U/mL, prior to the booster vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"21","spread":null},{"groupId":"OG002","value":"33","spread":null},{"groupId":"OG003","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti- PRP Antibody Concentrations","description":"Anti-PRP antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in microgram per milliliter (μg/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.683","spread":null},{"groupId":"OG001","value":"4.507","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti- PRP Antibody Concentrations.","description":"Anti-PRP antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in microgram per milliliter (μg/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.703","spread":null},{"groupId":"OG001","value":"5.312","spread":null},{"groupId":"OG002","value":"2.837","spread":null},{"groupId":"OG003","value":"2.904","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-D and Anti-T Antibody Concentrations.","description":"Anti-D and anti-T antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in International Units per milliliter (IU/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.117","spread":null},{"groupId":"OG001","value":"0.077","spread":null},{"groupId":"OG002","value":"0.162","spread":null},{"groupId":"OG003","value":"0.145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.397","spread":null},{"groupId":"OG001","value":"0.512","spread":null},{"groupId":"OG002","value":"0.588","spread":null},{"groupId":"OG003","value":"0.446","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-HBs Antibody Concentrations.","description":"Anti-HBs antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in milli International Units per milliliter (mIU/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":null},{"groupId":"OG001","value":"26.1","spread":null},{"groupId":"OG002","value":"70.5","spread":null},{"groupId":"OG003","value":"43.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Anti-BPT Antibody Concentrations.","description":"Anti-BPT antibody concentrations are presented as geometric mean concentrations (GMCs), expressed in ELISA units per milliliter (EL.U/mL), as assessed by ELISA.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"10.7","spread":null},{"groupId":"OG002","value":"12.8","spread":null},{"groupId":"OG003","value":"11.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were drowsiness, fever \\[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 fever = fever \\> 39.5 °C. Grade 3 irritability = crying that could not be comforted and prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = symptom assessed by the investigator as related to the vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms.","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = cried when limb was moved/spontaneously painful. Grade 3 redness/swelling = redness/swelling spreading beyond 20 millimeters (mm) of injection site.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"303","spread":null},{"groupId":"OG002","value":"181","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"34","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"255","spread":null},{"groupId":"OG002","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"58","spread":null},{"groupId":"OG002","value":"50","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"250","spread":null},{"groupId":"OG002","value":"140","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"84","spread":null},{"groupId":"OG002","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms.","description":"Assessed solicited general symptoms were drowsiness, fever \\[defined as axillary temperature equal to or above (≥) 37.5 degrees Celsius (°C)\\], irritability and loss of appetite. Any = occurrence of the symptom regardless of intensity grade. Grade 3 drowsiness = drowsiness that prevented normal activity. Grade 3 fever = fever \\> 39.5 °C. Grade 3 irritability = crying that could not be comforted and prevented normal activity. Grade 3 loss of appetite = not eating at all. Related = symptom assessed by the investigator as related to the vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"174","spread":null},{"groupId":"OG002","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"174","spread":null},{"groupId":"OG002","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"270","spread":null},{"groupId":"OG002","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"270","spread":null},{"groupId":"OG002","value":"168","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"267","spread":null},{"groupId":"OG002","value":"162","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54","spread":null},{"groupId":"OG001","value":"266","spread":null},{"groupId":"OG002","value":"161","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"129","spread":null},{"groupId":"OG002","value":"79","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":85},"commonTop":["Pain (post-booster)","Fever (Axillary) (post-booster)","Iritability (post-booster)","Redness (post-booster)","Swelling (post-booster)"]}}}